Welcome to our dedicated page for Arcadia Bioscien news (Ticker: RKDA), a resource for investors and traders seeking the latest updates and insights on Arcadia Bioscien stock.
Arcadia Biosciences, Inc. reports developments tied to its plant-based health and wellness products business, including Zola coconut water and agronomic wheat traits. Company news includes operating and financial results, business highlights, material agreements, shareholder voting matters, and capital-structure actions involving its publicly traded common stock.
Recurring updates also cover governance matters, security-structure disclosures, and other corporate events that affect the company's financing, reporting, and operating profile.
Arcadia Biosciences (Nasdaq: RKDA) reported second quarter 2026 revenues of $1.44 million, down 1% year over year, and first half revenues of $2.54 million, down 4%. Q2 loss from continuing operations was $0.5 million, while net loss attributable to common stockholders widened to $6.3 million, or $2.09 per share.
First half 2026 net loss attributable to common stockholders was $10.7 million, or $4.19 per share. According to the company, Q2 net results reflected a $2.8 million unrealized loss on Above Food stock, a $5.4 million valuation loss on a June 2026 PIPE, and offering costs. Net cash used in operating activities was $319,000 in Q2, and Arcadia ended the quarter with $4.2 million in cash after a $4 million June private placement. SG&A expenses declined by $1.0 million in Q2 and $1.6 million in the first half versus 2025, driven by lower employee costs and no M&A fees. Zola revenues fell 4% in the first half, but July Zola sales exceeded $740,000 and surpassed $1 million through the first week of August, following resolution of inventory and shipping issues.
Arcadia Biosciences (Nasdaq: RKDA) closed a $4 million private placement priced at-the-market under Nasdaq rules. Investors purchased 3,883,496 common shares (or pre-funded warrants) plus Series A-1 and Series A-2 preferred investment options at $1.03 per share.
Series A-1 and A-2 options have a $0.91 exercise price, with different exercisability and expiry terms. Net proceeds will fund working capital and general corporate purposes. The securities are unregistered, with Arcadia agreeing to file resale registration statements with the SEC.
Arcadia Biosciences (Nasdaq: RKDA) entered securities purchase agreements for a $4 million private placement priced at-the-market under Nasdaq rules.
Investors will buy 3,883,496 common shares (or pre-funded warrants) plus Series A-1 and A-2 preferred investment options, with exercise prices of $0.91 per share.
Proceeds will fund working capital and general corporate purposes.
Arcadia Biosciences (Nasdaq: RKDA) reported first quarter 2026 results. Zola coconut water unit volumes rose 18% year-over-year, supported by a price increase, though total revenues declined 8% to $1.1 million.
Total operating expenses climbed to $1.9 million, while SG&A reached the lowest level in company history. Net loss attributable to common stockholders was $4.4 million, versus $2.6 million net income a year earlier, impacted by a $2.9 million warrant inducement loss. Arcadia also received approximately $2.1 million in gross proceeds from exercises of preferred investment options.
Arcadia Biosciences (Nasdaq: RKDA) reported Q4 and full-year 2025 results and business updates on March 26, 2026. The company said it received a termination notice for the proposed Roosevelt Resources business combination and raised approximately $2.1 million from exercise of preferred investment options.
Zola coconut water revenues rose 17% YoY. SG&A expense declined ~27%, net cash used in operating activities fell 49%, Q4 revenue was $0.9M vs $1.2M prior year, and full-year revenue was $4.858M vs $5.045M in 2024. Q4 net loss attributable to common stockholders was $1.336M (Q4 2024: $4.064M).
Arcadia Biosciences (Nasdaq: RKDA) agreed to immediate exercises of certain preferred investment options to purchase up to 808,595 shares at a reduced exercise price of $2.575 per share, generating approximately $2.1 million gross proceeds before fees. In exchange, Arcadia will issue new unregistered preferred investment options to buy up to 1,617,190 shares at an exercise price of $2.325, exercisable immediately and expiring 30 months after the Resale Registration Statement effective date. The offering is expected to close on or about January 12, 2026, with H.C. Wainwright & Co. as placement agent.
Net proceeds are intended for working capital and general corporate purposes.
Arcadia Biosciences (Nasdaq: RKDA) said it received a termination notice from Roosevelt Resources on December 24, 2025, ending the Securities Exchange Agreement dated December 4, 2024 for a proposed business combination.
The company said it will resume evaluating strategic alternatives to create shareholder value. Management noted operational streamlining, reduced operating expenses, growth of the Zola coconut water brand, and avoidance of long-term debt over the past two-and-a-half years. Arcadia also reported it continues to own approximately 2.7 million shares of Above Food Ingredients common stock and stated it believes it is entitled to additional consideration relating to its May 2024 sale of GoodWheat.
Arcadia Biosciences (Nasdaq: RKDA) reported third quarter 2025 results on Nov 7, 2025 showing mixed operating performance and balance sheet activity.
Zola year-to-date revenue rose 26% driven by increased distribution; third-quarter revenues were flat year‑over‑year. Gross profit margins exceeded 30% for the 11th consecutive quarter. Cash declined by $257K to $1.1M. The company recognized a $4.7M credit loss/b) related to an outstanding promissory note and received ~ shares of Above Food Ingredients as partial repayment.
Arcadia Biosciences (NASDAQ:RKDA) reported Q2 2025 financial results, with total revenues increasing 11% year-over-year to $1.46 million, driven by 24% growth in Zola® coconut water sales. The company maintained gross margins above 30% for ten consecutive quarters.
Key developments include receiving 2.7 million shares of Above Food Ingredients (ABVE) stock as partial repayment of a $6 million note receivable from the GoodWheat™ assets sale, and eliminating $1 million in contingent liabilities through an agreement with Bioseed Research India. However, the company recognized a $4.5 million credit loss related to the Above Food note receivable.
Q2 2025 resulted in a net loss of $4.46 million ($3.26 per share), compared to net income of $1.06 million in Q2 2024. The company's pending business combination with Roosevelt Resources continues to progress with an amended Form S-4 registration statement filed.